Headquarters
UK
Every company in the roster headquartered in UK.
Research
Compare company financial metrics
Research adds sourced market cap, cash, runway and annualized R&D figures with metric-specific sorting.
Views
8 of 8 companies
| Company | Pipeline | Most advanced | Next readout |
|---|---|---|---|
 AstraZenecaAZN · Nasdaq | 78 assets: 28 approved, 21 Ph 3, 19 Ph 2, 10 Ph 1 | AZD0780Phase 3 · Atherosclerotic Cardiovascular DiseaseReliable signal | 19 Oct 2026Benralizumab · Approved |
 GlaxoSmithKlineGSK · NYSE | 59 assets: 27 approved, 15 Ph 3, 12 Ph 2, 4 Ph 1, 1 other | fluticasone propionate/salmeterolPhase 3 · AsthmaReliable signal | 13 Oct 2026Dostarlimab · Phase 1/2 |
 Apollo TherapeuticsPrivate | 3 assets: 2 Ph 2, 1 Ph 1 | camoteskimabPhase 2 · Atopic DermatitisPartial signal | 1 Mar 2027APL-4098 · Phase 1 |
 Mereo BioPharmaMREO · Nasdaq | 2 assets: 1 Ph 3, 1 Ph 2 | setrusumabPhase 3 · Osteogenesis Imperfecta | None on record |
 Arecor LimitedAREC · AIM | 1 asset: 1 Ph 1 | AT278Phase 1 · Type 2 DiabetesPartial signal | None on record |
 Grey Wolf TherapeuticsPrivate | 1 asset: 1 Ph 2 | GRWD5769Phase 1/2 · Non-Small Cell Lung Cancer | 30 Apr 2027GRWD5769 · Phase 1/2 |
 MicrobioticaPrivate | 1 asset: 1 Ph 1 | MB310Phase 1 · Ulcerative ColitisPartial signal | None on record |
 NodTheraPrivate | 1 asset: 1 Ph 2 | NT-0796Phase 2 · ObesityPartial signal | None on record |
Next readout: the earliest estimated primary completion of a trial the company or a partner on the asset runs (ClinicalTrials.gov).